Q3 2010

Filed Nov 12, 2010 · 10-Q · 43 days after period end · 0000950123-10-104893

Q3 2010 · 10-Q

Revenue—

Net Income

-$13.54M

no prior Q3 2009 on file

EPS Diluted

-$3.47

no prior Q3 2009 on file

Operating Income-$3,635,000—

Operating Cash Flowderived-$4,535,000—

Same quarter

no prior Q3 2009 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Sep 30, 2010 · filed Nov 12, 2010 · 43 d after period end

Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR